RFK Jr. Peptide Reclassification Tracker: Category 2 Removals and PCAC July 2026

The path from 19 restricted peptides to the current reclassification process involved lawsuits, political intervention, nomination withdrawals and a change in administration. Here is every significant step.

The February 2026 announcement is the political event that set this reclassification in motion, and it has been both widely cited and widely misrepresented. Here is what Kennedy actually committed to, versus what was inferred.

Kennedy stated that he is “a big fan of peptides” and has “used them myself to really good effect on a couple of injuries.” He framed the 2023 Category 2 restrictions as regulatory overreach that “created the grey market” by driving patients toward unregulated vendors with no pharmaceutical oversight, sterility testing or quality controls. He said approximately 14 of the 19 restricted peptides would move back toward Category 1 status, and acknowledged that litigation prevented reinstating all 19.

What he did not say – and what many peptide vendors, wellness clinics and social media accounts subsequently claimed – was that peptides would be immediately available, that they were now legal to compound, or that the FDA had approved them. He announced a political direction, not a regulatory conclusion. The April 2026 Category 2 removals and PCAC scheduling represent the formal procedural steps needed to convert that direction into policy.

On 15 April 2026, the FDA announced removal of 12 peptide bulk drug substances from Category 2 because the original nominations placing them there had been withdrawn by their nominators – the same procedural mechanism used in September 2024 when five peptides were removed ahead of the Oct/Dec PCAC sessions.

Additionally, GHK-Cu for non-injectable routes of administration was separately removed from Category 1 (also due to nomination withdrawal). Both GHK-Cu entries are scheduled for PCAC consultation before February 2027.

Of these 12, seven are scheduled for PCAC review on 23-24 July 2026 (BPC-157, KPV, TB-500, MOTS-C, Emideltide, Semax, Epitalon). The remaining five (LL-37, Dihexa, GHK-Cu injectable, PEG-MGF, Melanotan II) are deferred to a second session before February 2027.

Not all 19 original peptides have moved forward. Kennedy said “approximately 14” would be reclassified, and the numbers broadly align with that figure – but the specifics are worth tracking.

GHRP-2 and GHRP-6 remain on Category 2 with their nominations intact and no review scheduled. These are growth hormone releasing peptides with more pronounced side-effect profiles than other GH secretagogues – stronger cortisol and prolactin elevation, and in GHRP-6’s case, significant appetite stimulation. The PCAC previously flagged the GHRP class for safety concerns during the October 2024 session.

Six peptides removed in September 2024 (CJC-1295, Ipamorelin, Thymosin Alpha-1, AOD-9604, Selank, and Ibutamoren/MK-677) went through PCAC review and received negative recommendations. They are not currently scheduled for re-review and their regulatory path forward remains unclear.

This table tracks every peptide from the original September 2023 Category 2 designation through its current regulatory position as of May 2026.

This story has been widely misreported, particularly by peptide vendors and wellness clinics eager to signal that restrictions have been lifted. Four critical distinctions need emphasis:

The PCAC rejected every peptide it reviewed in 2024, which raises an obvious question: why would this time be different? There are structural reasons it could be, and structural reasons it might not be.

The institutional environment has changed materially. The current administration has publicly signalled support for broader peptide access, unlike the Biden-era FDA that imposed the original restrictions. The PCAC has significant committee vacancies that Secretary Kennedy could fill before the July meeting, potentially changing the composition and orientation of the panel. Many prior FDA staff involved in the original Category 2 designations have departed the agency. Compounding pharmacy trade groups have filed lawsuits arguing the FDA lacked a proper safety signal to justify the 2023 restrictions in the first place, and the withdrawal of the original nominations by their nominators undermines the evidentiary basis for the restrictions.

On the other hand, the committee’s scientific evaluation criteria have not changed. The fundamental questions – is there sufficient human safety data, are there adequate characterisation and purity standards, is there reproducible evidence of efficacy for the specified indication – are the same questions that sank six peptides in 2024. Political momentum from HHS does not override scientific evaluation at the committee level, as the 2024 outcomes demonstrated. Whether the July 2026 nominators bring stronger dossiers than their predecessors is the variable that will matter most.

The regulatory divergence between jurisdictions is striking. The United States is moving toward restoring compounding access for peptides like BPC-157 and TB-500. Australia’s TGA has been moving in the opposite direction – adding BPC-157 to Schedule 4 in June 2024 and escalating Melanotan II to Schedule 9 (prohibited) in February 2026. The UK’s MHRA has maintained a more moderate enforcement posture focused on supply-side action against vendors making therapeutic claims. Neither the TGA nor the MHRA has indicated any intention to adjust its approach in response to US developments.

What did RFK Jr. actually say about peptides?

On the Joe Rogan Experience (Episode #2461, 27 February 2026), HHS Secretary Kennedy stated that approximately 14 of the 19 Category 2 peptides would return to legal compounding status. He argued the restrictions created the grey market they were intended to prevent, described himself as a supporter of peptide therapies, and criticised the prior administration’s handling of peptide policy. He acknowledged that litigation prevented reinstating all 19. He did not announce immediate availability or FDA approval.

Are peptides legal to compound again in 2026?

Not yet, as of May 2026. Twelve peptides have been removed from Category 2, but they have not been placed on the 503A Bulks List. The PCAC meeting on 23-24 July 2026 will review seven of them for potential inclusion. Formal compounding access requires a positive PCAC recommendation followed by FDA rulemaking, with realistic pharmacy availability no earlier than late 2026.

Why were peptides banned from compounding in 2023?

In September 2023, the Biden-era FDA assigned 19 peptides to Category 2, citing insufficient human safety data, potential for immunogenicity, concerns about peptide-related impurities, aggregation risk, and sterility challenges. Compounding pharmacy trade groups challenged the designations as overreach, arguing the FDA lacked a specific safety signal for most of the affected substances. The withdrawal of the original nominations by their nominators in 2026 suggests the evidentiary basis for the restrictions was weaker than the FDA initially claimed.

Which peptides will stay restricted?

GHRP-2 and GHRP-6 remain on Category 2 with no scheduled review. Six peptides removed in September 2024 (CJC-1295, Ipamorelin, Thymosin Alpha-1, AOD-9604, Selank, and Ibutamoren) received negative PCAC recommendations and are not currently eligible for compounding. Five peptides from the April 2026 removal (LL-37, Dihexa, GHK-Cu injectable, PEG-MGF, Melanotan II) are deferred to a second PCAC session before February 2027.

Does this affect peptide legality in Australia or the UK?

No. The FDA’s actions have no bearing on peptide regulation in Australia or the United Kingdom. The TGA and MHRA operate independent regulatory frameworks. Australia has been moving in the opposite direction, with BPC-157 added to Schedule 4 and Melanotan II escalated to Schedule 9.